REFRACTORY MARGINAL ZONE LYMPHOMA
Clinical trials for REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
Disease control OngoingThis study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test new drug duo in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Early trial tests new arsenal against stubborn blood cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a three-drug combination for patients with slow-growing non-Hodgkin's lymphoma that has returned or not responded to prior treatment. The drugs work together to help the immune system attack cancer cells and block a pr…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Three-Drug attack on tough lymphomas
Disease control OngoingThis study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for patients Who've run out of options: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC